Trials / Completed
CompletedNCT02023268
Efficacy and Safety of T2762 and Vismed® in Dry Eye Syndrome
Phase III: Comparison of the Efficacy and Safety of T2762 and Vismed® in the Treatment of Moderate to Severe Dry Eye Syndrome
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 105 (actual)
- Sponsor
- Laboratoires Thea · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Comparison of the efficacy and safety of T2762 and Vismed® in the treatment of moderate to severe Dry Eye Syndrome
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | T2762 | 1 drop in each eye 3 to 6 times daily during 84 days |
| DEVICE | Vismed® | 1 drop in each eye 3 to 6 times daily during 84 days |
Timeline
- Start date
- 2013-12-01
- Primary completion
- 2014-12-01
- Completion
- 2015-02-01
- First posted
- 2013-12-30
- Last updated
- 2017-08-24
- Results posted
- 2016-04-06
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT02023268. Inclusion in this directory is not an endorsement.